Volume 98, Issue 6 pp. 517-524
ORIGINAL ARTICLE

Immunohistochemical detection of “ex novo” HLA-DR in tumor cells determines clinical outcome in laryngeal cancer patients

Chiara Prampolini

Chiara Prampolini

Department of Head-Neck and Sensory Organs, Università Cattolica del Sacro Cuore, Rome, Italy

Search for more papers by this author
Giovanni Almadori

Giovanni Almadori

Department of Head-Neck and Sensory Organs, Università Cattolica del Sacro Cuore, Rome, Italy

Department of Aging, Neurologic, Orthopedic and Head-Neck Sciences, Otorhinolaryngology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Search for more papers by this author
Davide Bonvissuto

Davide Bonvissuto

Department of Neurosciences, Università Cattolica del Sacro Cuore, Rome, Italy

Search for more papers by this author
Marta Barba

Marta Barba

Department of Life Science and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy

Biobank for Personalized Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Search for more papers by this author
Luca Giraldi

Luca Giraldi

Department of Life Science and Public Health, Section of Hygiene and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy

Search for more papers by this author
Stefania Boccia

Stefania Boccia

Department of Life Science and Public Health, Section of Hygiene and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy

Department of Woman and Child Health and Public Health, Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Search for more papers by this author
Gaetano Paludetti

Gaetano Paludetti

Department of Head-Neck and Sensory Organs, Università Cattolica del Sacro Cuore, Rome, Italy

Department of Aging, Neurologic, Orthopedic and Head-Neck Sciences, Otorhinolaryngology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Search for more papers by this author
Jacopo Galli

Jacopo Galli

Department of Head-Neck and Sensory Organs, Università Cattolica del Sacro Cuore, Rome, Italy

Department of Aging, Neurologic, Orthopedic and Head-Neck Sciences, Otorhinolaryngology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Search for more papers by this author
Ornella Parolini

Ornella Parolini

Department of Life Science and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy

Biobank for Personalized Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Search for more papers by this author
Stefano Settimi

Corresponding Author

Stefano Settimi

Department of Aging, Neurologic, Orthopedic and Head-Neck Sciences, Otorhinolaryngology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Correspondence

Stefano Settimi, Department of Aging, Neurologic, Orthopedic and Head-Neck Sciences, Otorhinolaryngology Unit, Fondazione Policlinico Universitario “A. Gemelli” – IRCCS, Largo A. Gemelli, 8 00168 Rome, Italy.

Email: [email protected]

Search for more papers by this author
Gabriella Cadoni

Gabriella Cadoni

Department of Head-Neck and Sensory Organs, Università Cattolica del Sacro Cuore, Rome, Italy

Department of Aging, Neurologic, Orthopedic and Head-Neck Sciences, Otorhinolaryngology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Search for more papers by this author
First published: 03 October 2021
Citations: 1

Abstract

There are controversial results about the role of “ex novo” HLA-DR expression by tumor cells and its correlation with the oncological outcomes. Unfortunately, little is known about HLA-DR expression in laryngeal cancer tumor cells. The main purpose of this retrospective study is to strengthen the usefulness of studying “ex novo” HLA-DR expression on tumor cells from primary laryngeal squamous cell carcinoma (LSCC) patients and investigate its correlation with clinical outcome. We analyzed HLA-DR expression by immunohistochemical analysis in 56 patients with LSCC. The “ex novo” HLA-DR expression on laryngeal cancer tumor cells, assessing non-neoplastic LSCC – adjacent tissue, and the association of HLA-DR expression (HLA-DR+) with clinical outcomes were investigated. HLA-DR+ tumor cells were detected in 18/56 LSCC patients (32.1%). All specimens of non-neoplastic laryngeal carcinoma-adjacent tissue resulted HLA-DR negative (HLA-DR-). A statistically significant association was observed between HLA-DR + and well differentiated tumors (G1) (p<0.001). The Kaplan-Meier method showed how HLA-DR+ is significantly associated with both a better disease specific survival (HLA-DR+=100% vs. HLA-DR-=77.4%; p=0.047) and a better relapse free survival (HLA-DR+=100% vs. HLA-DR-=72.3%; p=0.021). Cox regression univariate analysis for death of disease confirmed a higher HR for HLA-DR absence on the surface of epithelial tumor cell [HR:37.489; 95% CI:0.750-18730.776; p=0.253] and for high-grade (G3) tumors [HR:18.601; 95% CI:3.613-95.764; p<0.0001]. Our results confirm that MHC class II HLA-DR expression is activated in a sub-set of LSCC patients. Evaluation of HLA-DR expression in LSCC could be useful for prognosis and future approaches towards personalized therapy.

CONFLICT OF INTEREST

The authors declare that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.